mazzhome

The Global Retinal Disease Therapeutics Market is likely to expand at an impressive rate driven by recent government participation towards the prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled “Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.

Browse Complete Report Details @

https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311

The Global Retinal Disease Therapeutics Market is consolidated in nature, with only a handful of market players accounting for the maximum share of the market. With consolidation, it is becoming increasingly difficult for newer market entrants to establish a stronghold or derive immediate success. Therefore the global market is boosted by-products and concepts introduced by existing companies.

North America to Emerge Dominant in the Forecast Period

The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the global retinal disease therapeutics market in recent years. The Retinal Disease Therapeutics Market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years.

Improved health infrastructures, increasing patient pool, and favorable health reimbursement policies are some of the factors that are likely to boost the regional market in the forthcoming years. High prevalence of retinal diseases in the Asia Pacific is a major reason why this region is estimated to rise with the highest CAGR in the forecast period.

1. Hoffmann-La Roche AG’s ‘Lucentis’ is Gaining Increasing Popularity

The diabetic retinopathy is a severe kind of disorder that has accounted for the majority of cases of blindness in the US. Lucentis was an instant hit among healthcare professionals after it was backed by a series of clinical trials and approvals from the National Institute of Health (NIH).

Sample PDF Brochure @

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/retinal-disease-therapeutics-market-100311

One such instance of this development is the “Lucentis” therapy, put forward by F. Hoffmann-La Roche AG. Lucentis was introduced to provide therapeutic advice and development of products for patients suffering from chronic disease. In 2017, the Food and Drug Administration (FDA) approved Lucentis for diabetic retinopathy.

Some of the Main Key Players Covered in the Report

  • Merck
  • Novartis
  • Allergan
  • Roche
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical

Excellent clinical effects of Lucentis have led to a subsequent rise in demand for medicine among patients. The increasing demand has contributed to the growth of the global retinal disease therapeutics market and is likely to favor the market in the forthcoming years.

Segmentation:

By Disease Indication

  • Macular Degeneration
  • Diabetic Retinopathy
  • Diabetic Macular Edema
  • Retinal Vein Occlusion

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook and SWOT analysis:

6. North America Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026

6.1. Key Findings / Summary

6.2. Market Analysis By Disease Indication

6.2.1 Macular Degeneration

6.2.2 Diabetic Macular Edema

6.2.3 Diabetic Retinopathy

6.2.4 Retinal Vein Occlusion

6.2.5 Others

6.3. Market Analysis By End User

6.3.1 Hospital Pharmacy

6.3.2 Retail Pharmacy

6.3.3 Others

6.4. Market Analysis By Country

6.4.1 U.S.

6.4.2 Canada

7 Europe Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026

7.1. Key Findings / Summary

7.2. Market Analysis By Disease Indication

7.2.1 Macular Degeneration

7.2.2 Diabetic Macular Edema

7.2.3 Diabetic Retinopathy

7.2.4 Retinal Vein Occlusion

7.2.5 Others

7.3. Market Analysis By End User

7.3.1 Hospital Pharmacy

7.3.2 Retail Pharmacy

7.3.3 Others

7.4. Market Analysis By Country

7.4.1 Germany

7.4.2 U.K.

7.4.3 France

7.4.4 Italy

7.4.5 Spain

7.4.6 Scandinavia

7.4.7 Rest of Europe

8. Asia Pacific Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026

8.1. Key Findings / Summary

8.2. Market Analysis By Disease Indication

8.2.1 Macular Degeneration

8.2.2 Diabetic Macular Edema

8.2.3 Diabetic Retinopathy

8.2.4 Retinal Vein Occlusion

8.2.5 Others

8.3. Market Analysis By End User

8.3.1 Hospital Pharmacy

8.3.2 Retail Pharmacy

8.3.3 Others

8.4. Market Analysis By Country

8.4.1 India

8.4.2 China

8.4.3 Japan

8.4.4 Australia

8.4.5 Southeast Asia

8.4.6 Rest of Asia Pacific

More Trending Topics from Fortune Business Insights:

US$ 8,046.3 Mn by 2026; Pain Management Devices Market|Industry Outlook, Comprehensive Insights, Growth and Forecast

Hemodialysis Equipment Market 2019| Global Size, Recent Trends, Opportunity Assessment, Advanced Technology, Extensive Applications and Global Industry Overview

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Retinal Disease Therapeutics Market 2019 Report Highlights the Competitive Scenario with Impact of Drivers And Challenges 2026